Barricaid Annular Closure Device
Intrinsic Therapeutics · Decision date Mar 24, 2026
What did the FDA decide?
FDA records P160050/S012 as a supplement to PMA P160050, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 24, 2026.
FDA approval order statement
approval for an alternate manufacturing process and new supplier affecting critical components of the Barricaid implant device/delivery system, specifically the 8mm Delivery Sheath
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Mar 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160050/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Intrinsic Therapeutics
- Product code
- QES
- Decision code
- OK30
- Decision date
- Mar 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Reherniation reduction device.
- Applicant
- Intrinsic Therapeutics
- Product code
- QES
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160050/S010 · Related supplement
Barricaid Annular Closure Device
P160050/S011 · Related supplement
Barricaid Annular Closure Device
P160050/S012 received
Application receipt date recorded by FDA.
P160050/S012 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P160050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160050
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Barricaid Annular Closure DeviceP160050/S010 | Intrinsic Therapeutics | PMA supplement | Oct 9, 2025 | FDA |
Barricaid Annular Closure DeviceP160050/S011 | Intrinsic Therapeutics | PMA supplement | Dec 18, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Intrinsic Therapeutics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 30 Commerce Way, Woburn, MA, 01801
Sources and methodology
- Original FDA record: P160050/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
